Basel Tourismus

Basel Tourismus kindly offers participants of the ISFMS2017 Conference the possibility to use their booking system to obtain the best rates for Hotels in Basel. Click the link to the booking system to reserve a room.

Welcome to Basel! We are proud to host such an eminent group of scientists in our city. On the other hand, we may modestly say, that this location is ideal for a high level symposium on molecular science in general and on cancer medication in particular.

Basel is a hot spot for Life Sciences. The Life Sciences form the basis of our economy and are an important source of our public wealth. Moreover Basel has an all-embracing scientific ecosystem in the Life Sciences.  The two global players Novartis and Roche alone contribute a volume of about 6 billion Swiss francs from Life Science Research. Although financed at a much lower level our University has a strong focus and hits well above its size in the Life Sciences – a knowledge pipeline beginning with the basic research at the Biozentrum and continuing along a translational path to the clinical research and practical application in the University Hospitals. The University is associated with renowned research institutes such as the Friedrich Miescher Institute of Novartis and the Swiss Tropical and Public Health Institute (Swiss TPH), which, like the University is a public institution. Of course the University also cooperates with top Universities in Switzerland – especially the ETH Zurich – and worldwide. There is also a close cooperation with our regional University of Applied Sciences.

If you look out of the window you will see the Life Science Campus arising, on which you soon will find the ETH-Department of Bio Systems and Systems Engineering in close vicinity to our university-institutes, such as the departments of Chemistry and Physics, the Biozentrum and the Department of  Biomedical Science. In the same area we find the campus of our University hospital. We thus combine all of the essential components for a successful translation from high end research to clinical application in an area less than a square kilometre.

How can this be done by a little administrative region such as Basel City with only 190‘000 inhabitants? It is possible because of strong regional partnerships, especially with our neighboring county, that sends the greatest cohort of students to the University of Basel. Our entire region is proud of its university and participates to its wellbeing, financially, culturally and emotionally. And of course there are the subsidies of the federal government as well as national and international research grants which are acquired with great success by our university and provide the fuel for the research engine. The whole ecosystem is embedded in a trinational region, where the three nations France, Germany and Switzerland meet and form one of the strongest Life-Science clusters of the world. A region of frontiers, ideally prepared to test and move beyond the frontiers in molecular sciences!

In Basel you encounter a curious combination of small town with a strong identity and a worldwide scientific impact. We believe this to be a unique strength of this area. The short distance between centres of excellence facilitates free exchange between scientists and leads to an openness to other cultures and a profound commitment to the improvement of life quality worldwide. Your meeting here is a fine signal of this Ambition.

With this brief welcome note I hope to have shown, that you have chosen excellent surroundings for your congress. I wish you inspiration, a good atmosphere and of course scientific success. However, please don’t forget to explore our other highlights: the fine architecture of Basel, the cultural highlights and, of course, the culinary opportunities. In short: I hope you will also find a little time for leisure and enjoyment during your stay here.   

Aeschimann Florian
Friedrich Miescher Institute Basel, Switzerland
florian.aeschimann@fmi.ch

Agami Reuven
Netherlands Cancer Institute, Amsterdam, The Netherlands
r.agami@nki.nl

Angermaier Johanna
Charité Universitätsmedizin Berlin, Germany
johanna.angermaier@charite.de

Askarian-Amiri Marjan
University of Auckland, New Zealand
m.askarian-amiri@auckland.ac.nz 

Avni Dror
Sheba Medical Center, Tel Hashomer, Israel
droravni@msn.com

Bar-Eli Menashe
The University of Texas, Houston, USA
mbareli@mdanderson.org

Battino Maurizio
Università Politecnica delle Marche, Italy
m.a.battino@univpm.it

Behera Alok
ETH Zurich, Switzerland
alok.behera@pharma.ethz.ch

Berger Stefanie
University of Basel, Switzerland
st.berger@unibas.ch

Biswas Roopa
Walter Reed National Military Medical Center, Bethesda, USA
roopa.biswas@usuhs.edu

Bjørklund Sunniva
Oslo University Hospital, Oslo, Norway
sunniva.bjorklund@gmail.com

Boeri Mattia
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
mattia.boeri@istitutotumori.mi.it

Bojar Daniel
ETH Zurich, Switzerland
daniel.bojar@bsse.ethz.ch

Brancati Giovanna
Friedrich Miescher Institute Basel, Switzerland
giovanna.brancati@fmi.ch

Burkhalter Matthias
MDPI Basel, Switzerland
burkhalter@mdpi.com

Bustin Stephen
Anglia Ruskin University, UK
stephen.bustin@anglia.ac.uk

Calin George A.
The University of Texas, Houston, USA
gcalin@mdanderson.org

Candi Eleonora
University of Rome, Rome, Italy
candi@uniroma2.it

Cascione Luciano
Institute of Oncology Research, Bellinzona, Switzerland
luciano.cascione@ior.iosi.ch

Catuogno Silvia
Istituto per l'endocrinologia e l'oncologia, Napoli, Italy
silviacatuogno@virgilio.it

Chen Yue
MDPI Wuhan, China
yue.chen@mdpi.com

Coe Elizabeth
University of Bath, UK
eac51@bath.ac.uk

Coscujuela Tarrero Lucia
University of Turin, Orbassano, Italy
lucykosky@gmail.com

Cramer Conradin
Regierungsrat Kanton Basel-Stadt
conradin.cramer@bs.ch

Cristina Vinci
University of Milan, Italy
cristina.vinci@unimi.it

Croce Carlo
The Ohio State University, Columbus, USA
carlo.croce@osumc.edu

Cuculovic Milos
MDPI Basel, Switzerland
cuculovic@mdpi.com

Daum Janine
Friedrich Miescher Institute Basel, Switzerland
janine.daum@fmi.ch

Degen Michèle
MDPI Basel, Switzerland
degen@mdpi.com

Diederichs Sven
Deutsches Krebsforschungszentrum, Heidelberg, Germany
s.diederichs@dkfz.de

Eichmüller Stefan
Deutsches Krebsforschungszentrum, Heidelberg, Germany
s.eichmueller@dkfz.de

Enguita Francisco
University of Lisbon, Portugal
fenguita@fm.ul.pt

Esteller Manel
Bellvitge Biomedical Research Institute, Barcelona, Spain
mesteller@idibell.cat

Faridani Omid
Karolinska Institutet, Sweden
omid.faridani@licr.ki.se

Felley-Bosco Emanuela
University of Zurich, Switzerlandemanuela.felley-bosco@usz.ch

Ferracin Manuela
University of Bologna, Bologna, Italy
manuela.ferracin@unibo.it

Ferrero Giulio
University of Turin, Torino, Itay
giulio.ferrero@unito.it

Fodor Barna
Novartis Institutes for BioMedical Research, Basel, Switzerland
barna.fodor@novartis.com

Freeland Alistair
MDPI Basel, Switzerland
freeland@mdpi.com

Fuentes-Mattei Enrique
MD Texas Cancer Center, Houston, USA
efuentes1@mdanderson.org

Ghoshal Kalpana
The Ohio State University, Columbus, USA
ghoshal.1@osu.edu

Grosshans Helge
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
helge.grosshans@fmi.ch

Gruber Andreas
University of Basel, Basel, Switzerland
aj.gruber@unibas.ch

Guerin Delphine
MDPI Basel, Switzerland
guerin@mdpi.com

Haidar Ziyad
University of los Andes, Santiago de Chile, Chile
zhaidar78@gmail.com

Hauer Christian
Novartis, Basel, Switzerland
christian.hauer@novartis.com

Hellio Claire
Université de Bretagne Occidentale, France
claire.hellio@univ-brest.fr

Huang Qihong
The Wistar Institute, Philadelphia, USA
qhuang@Wistar.org

Hwang Dae-Yong
Konkuk University Medical Center, Seoul, Korea
hwangcrc@kuh.ac.kr

Jeronimo Carmen
University of Porto, Porto, Portugal
carmenjeronimo@ipoporto.min-saude.pt

Jia Xiaofeng
University of Maryland, USA
XJia@som.umaryland.edu

Jiang Yanrui
ETH Zurich, Switzerland
yanrui.jiang@bsse.ethz.ch

Johnson Rory
University of Bern, Switzerland
rory.johnson@dkf.unibe.ch

Kancherla Venkatesh
Universitätsspital Basel, Switzerland
venky198922@gmail.com

Klajic Jovana
Akershus University Hospital, Denmark
jjovana38@yahoo.com

Kluiver Joost
University Medical Center Groningen, Groningen, The Netherlands
j.l.kluiver@umcg.nl

Konert Madlen
GATC Biotech, Konstanz, Germany
m.konert@gatc-biotech.com

Kresoja-Rakic Jelena
University of Zurich, Switzerland
jelena.rakic@usz.ch

Krummheuer Jörg
Exiqon A/S, Vedbæk, Denmark
jgk@exiqon.com

Kunej Tanja
University of Ljubljana, Slovenia
tanja.kunej@bf.uni-lj.si

Kurek Roman
Exiqon
rok@exiqon.com

Li Qiao
University of Ottawa, Ottawa, Canada
qiaoli@uottawa.ca

Lin Sen
MDPI Basel, Switzerland
sen.lin@mdpi.com

Lin Shu-Kun
MDPI Basel, Switzerland
lin@mdpi.com

Lucic Matije
ETH Zurich, Zurich, Switzerland
matije.lucic@pharma.ethz.ch

Mapelli Sarah
Institute of Oncology Research, Bellinzona, Switzerland
sarah.mapelli@ior.iosi.ch

Martinez Maite Huarte
University of Navarra, Pamplona, Spain
clopezg@unav.es

Mattick John S.
University of New South Wales, Sydney, Australia
j.mattick@garvan.org.au

Mercado Nicolas
Novartis Institutes for BioMedical Research, Basel, Switzerland
nicolas.mercado@novartis.com

Mihaila Delia
MDPI Basel, Switzerland
mihaila@mdpi.com

Mowla Seyed Javad
Tarbiat Modares University, Tehran, Iran
sjmowla@modares.ac.ir

Muller Fabbri
University of Southern California, Los Angeles, USA
mfabbri@chla.usc.edu

Napoli Sara
Institute of Oncology Research, Bellinzona, Switzerland
sara.napoli@ior.iosi.ch

Nasrollahzadeh Sabet Mehrdad
University of Tehran, Tehran, Iran
dr.m.sabet@gmail.com

Negrini Massimo
University of Ferrara, Ferrara, Italy
ngm@unife.it

Noghero Alessio
University of Turin, Candiolo, Itay
alessio.noghero@ircc.it

Orom Ulf Andersson
Max Planck Institute for Molecular Genetics, Berlin, Germany
oerom@molgen.mpg.de

Pahlevan Kakhki Majid
Karolinska Institute, Solna, Sweden
Majid.pahlevan.kakhki@ki.se

Panatta Emanuele
University of Rome, Rome, Italy
panatta.emanuele@gmail.com

Parrella Paola
Laboratory of Oncology IRCCS Casa Sollievo della Sofferenza
pparrella@operapadrepio.it

Pasculli Barbara
Laboratory of Oncology IRCCS Casa Sollievo della Sofferenza
b.pasculli@operapadrepio.it

Pasquinelli Amy
University of California, San Diego, USA
apasquinelli@ucsd.edu

Pena Rodrigo
University of Zurich, Switzerland
rodrigo.pena@dmmd.uzh.ch

Pichler Martin
Medical University of Graz, Austria
martin.pichler@medunigraz.at

Porcellini Elisa
University of Bologna, Italy
elisa.porcellini3@unibo.it

Quintavalle Cristina
Universitätsspital Basel, Switzerland
cristina.quintavalle@usb.ch

Rani James Alva
Deutsches Krebsforschungszentrum, Heidelberg, Germany
alvarani@gmail.com

Ren Yong
MDPI Wuhan, China
yong.ren@mdpi.com

Reshadatian Marzieh
Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
m.reshadatian@yahoo.com

Rigoutsos Isidore
Thomas Jefferson University, Philadelphia, USA
Isidore.Rigoutsos@jefferson.edu

Rittman Martyn
MDPI Basel, Switzerland
rittman@mdpi.com

Russo Aniello
University of Campania Luigi Vanvitelli, Caserta, Italy
aniello.russo@unina2.it

Russo Lucia
MDPI Barcelona, Spain
lucia.russo@mdpi.com

Salehi Rasoul
Isfahan University of Medical Science, Isfahan, Iran
r_salehi@med.mui.ac.ir

Saxena Meera
University of Basel, Basel, Switzerland
meera.saxena@unibas.ch

Schmittgen Thomas
University of Florida, Gainesville, USA
tschmittgen@cop.ufl.edu

Seimiya Makiko
ETH Zurich, Switzerland
makiko.seimiya@bsse.ethz.ch

Shetty Sunil
University of Basel, Switzerland
sunil.shetty@unibas.ch

Skawran Britta
Medical School Hannover, Hannover, Germany
skawran.britta@mh-hannover.de

Slack Frank J.
Harvard Medical School, Boston, USA
fslack@bidmc.harvard.edu

Stiegelbauer Verena
Medical University of Graz, Austria
verena.stiegelbauer@medunigraz.at

Sylvester Bianca
MDPI Romania
bianca.sylvester@mdpi.com

Tahmasebi Maryam
Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
maryam_tahmaseby@yahoo.com

Terreri Sara
Institute of Genetics and Biophysics, Naples, Italy
sara.terreri@igb.cnr.it 

Uko Bubaraye
University of Liverpool, Liverpool, UK
b.uko@liv.ac.uk

Vajen Beate
Medical School Hannover, Hannover, Germany
vajen.beate@mh-hannover.de

Vandesompele Jo
Ghent University, Ghent, Belgium
Joke.Vandesompele@UGent.be

Vazquez Franck
MDPI Basel, Switzerland
vazquez@mdpi.com

Veronese Angelo
University of Chieti-Pescara, Italy
a.veronese@unich.it 

Wang Yun
Sun Yat-sen University, Guangzhou, China
pemberley05@hotmail.com

Wu Wei-Zhong
Fudan University, Shanghai, China
wu.weizhong@zs-hospital.sh.cn

Wu Zongsong
University of Basel, Switzerland
zongsong.wu@unibas.ch

Yap Yoon Sing
New York University School of Medicine, New York, USA
yoonsing.yap@nyumc.org

Zavolan Mihaela
University of Basel, Switzerland
mihaela.zavolan@unibas.ch

Zeitler Daniela
University of Regensburg, Germany
Daniela.Zeitler@ur.de

Zhang Shu
Xi'an Jiaotong University, China
drzhangshu@163.com 

Welcome Message by Dr. Conradin Cramer, Regierungsrat Kanton Basel-Stadt

Conradin Cramer with George Calin, Chair of ISFMS2017 and John Mattick, Member of the Scientific Committee

Witold Filipowicz, FMI Basel, John Mattick, University of New South Wales and Conradin Cramer

Amy Pasquinelli University of California, San Diego, USA

Coffee Break at the Biocenter, University of Basel

Qihong Huang, The Wistar Institute, Philadelphia, USA

Sven Diederichs, DKFZ, Heidelberg, Germany

Carlo Croce, The Ohio State University, Columbus, USA

Poster Exhibition

The conference team. Lucia Russo, Daniel Luong and Michèle Degen

John Mattick and Franck Vazquez

Helge Grosshans, FMI Basel, Switzerland

Fabbri Muller, University of Southern California, Los Angeles, USA

John Mattick

Franck Slack and Helge Grosshans

Mihaela Zavolan, University of Basel, Switzerland

George Calin, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Franck Vazquez, Lucia Russo, Michèle Degen and Matthias Burkhalter, MDPI AG, Basel and Barcelona

Tom Schmittgen, University of Florida, Gainesville, USA

Final talks at ISFMS2017

Jo Vandesompele, Ghent University, Belgium

Tom Schmittgen and George Calin

Sara Terreri, Winner of the Best Poster Award

Franck Vazquez, CEO, MDPI AG, Basel, Switzerland

George Calin and Franck Vazquez

The Sponsors, IJMS, Cancers and Non-Coding RNA, offers one award to our participants at the conference:

1. Best Poster Award (1): 1 waived publication in one of our journals. The nominations have been assessed by the Organizing Committee.

Winner: Sara Terreri, Institute of Genetics and Biophysics (IGB-ABT), National Research Council (CNR), Naples, Italy

Sara Terreri the Winner of the 'Best Poster Award' together with George Calin, Chair ISFMS2017 and Franck Vazquez, CEO MDPI AG

Expression and Functional Characterization of Ultraconserved Non-Coding Regions 8+ in Bladder Cancer

Sara Terreri¹, Sara Mancinelli¹, Dimitrios Papaioannou², Giovanna L. Liguori¹, Ramiro Garzon², Amelia Cimmino<sup>1

1</sup> Institute of Genetics and Biophysics (IGB-ABT), National Research Council (CNR), Naples, Italy.
² Division of Hematology, the Ohio State University, Comprehensive Cancer Center, Columbus, Ohio,
USA.

Transcribed ultraconserved regions (T-UCRs) represent a group of highly conserved sequences among orthologous regions of human, rat and mouse genomes. They represent a new class of long non-coding RNAs (lncRNAs) whose function is still unknown. While microRNAs and other types of lncRNAs have been shown to contribute to the biological function of bladder cancer (BlCa) and are increasingly being used to improve the clinical care of patients, this is not yet the case for T-UCRs. By using genome-wide profiling, we identified 293 T-UCRs de-regulated in BlCa patients as compared to normal tissues. T-UCR 8+ is the most up-regulated and inversely related to grade, paving the way for clinical applications. We demonstrated that T-UCR 8+ is localized in the cytoplasm of BlCa cells, suggesting that active molecular exportation could take place and be involved in cancer formation and/or progression. To better clarify the cytoplasmic function of T-UCR 8+ during tumorigenesis and understand its role, we dissect T-UCR 8+ protein network interaction using the RAP–MS method. As preliminary data, we purified T-UCR 8+ sequence and we are now performing the mass spectroscopy to verify which proteins bind to this lncRNA. To confirm its localization, we also performed ISH (In situ Hybridization) experiments in BlCa tissues and different embryo stages.

A conference video will be uploaded soon.

Registration Information

To register with this conference, please follow this link. If you need assistance, please e-mail the Conference Secretariat.

Early Registration Fees (until 5 May 2017)

• Academic, early: 700.00 CHF
• Scientific Board Members of the journal IJMS, early: 350.00 CHF
• MDPI Author* or Reviewer**, early: 600.00 CHF
• Student, early: 550.00 CHF
• Non-academic, early: 1100.00 CHF

Late Registration Fees (from 6 May 2017)

• Academic, Late: 800.00 CHF
• Scientific Board Members of the journal IJMS, late: 450.00 CHF
• MDPI Author* or Reviewer**, late: 700.00 CHF
• Non-academic, late: 1200.00 CHF

Waived Fees

• Waived Fees - Invited Speakers and MDPI Guests: 0.00 CHF: 0.00 CHF

Sponsored Rate (20 available)

• Special (0/20): 100.00 CHF

Conference Dinner

The registration fee must be paid latest one month after registration and includes attendance of all conference sessions, morning/afternoon coffee breaks and lunches, conference bag and program book. Other dinners are not included and are left at the convenience of attendees

For onsite registration, please contact the Conference Secretariat.

* First and last authors of articles published in 2014 or later will enjoy a discount.
**Reviewers who provided timely review reports in 2014 or later will enjoy a discount.

Prices are in CHF (Swiss Francs)

Cancellation Policy

Participation to the conference is considered final only once the registration fees have been paid. The number of participants is limited, once the number of paid registrations reaches the maximum number of participants, unpaid registrations will be cancelled.

Cancellation of paid registration is possible under the terms listed below:> 2 months before the conferenceFull refund but 100 CHF are retained for administration> 1 month before the conferenceRefund 50% of the applying fees> 2 weeks before the conferenceRefund 25% of the applying fees< 2 weeks before the conferenceNo refund

Visa Requirements

Citizens of the EU and the EFTA and their family members

• Citizens of EU and EFTA countries must present valid personal identification, an ID card or a passport. No visa required.
• Regardless of their citizenship, family members of EU and EFTA citizens must present a valid passport and they must have a specific residence permit from a Schengen country (no visa required). Otherwise a visa must be obtained.

For more information, see https://www.bfm.admin.ch/content/bfm/en/home/themen/einreise/kurzfristig/eu-efta-buerger.html.

• EU Countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.
• EFTA Countries: Iceland, Liechtenstein, Norway, Switzerland.
• Schengen Countries: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland.

Citizens of the USA and Canada

A valid travel passport is required. No visa required for stays of up to 90 days.

Third-Country Nationals

A valid travel passport is required and in some cases a visa must be obtained prior to entering Switzerland. For more information, check the column "Visa required for stays of up to 90 days" for your country in the Overview of ID and visa provisions according to nationality from the Swiss Office for Migration.

Traveling to Basel

For a complete overview, see wikitravel.org.

• By Plane: Basel can easily be reached by direct flights from many cities within Europe to the EuroAirport Basel-Mulhouse-Freiburg (IATA airport codes: MHL/BSL/EAP). Inter-continental travel to Basel is recommended via Amsterdam, Frankfurt, Paris or London airports. Remember to use the “Swiss Exit”, not the exit to France.
  Basel is readily connected within 30 minutes via the airport bus line 50 or by taxi.
  Another airport in the area includes Zurich International (ZRH).
• By Train: reachable from most major cities in France (via Strasbourg or Mulhouse), Germany (via Frankfurt a. M. or Mannheim) and Italy (via Milan). The two train stations Basel SBB and Basel Bad. are both conveniently connected with the city public transports (BVB). A mobility ticket for free use of public transport is provided by many hotels in Basel.

The program of the 2nd International Symposium on Frontiers in Molecular Science 'Non-Coding RNAs and Epigenetics in Cancer', Basel, is now available in the abstract book (last update June, 15).

	Wednesday 21 June 2017	Thursday 22 June 2017	Friday 23 June 2017
Morning	The Biology of ncRNAs Prof. Reuven Agami Prof. Amy Pasquinelli	Bioinformatics of ncRNAs Prof. Isidore Rigoutsos Prof. Mihaela Zavolan	ncRNA Technologies Prof. Thomas Schmittgen Prof. Jo Vandesompele
	Coffee Break	Coffee Break	Coffee Break
	The Biology of ncRNAs Prof. Qihong Huang Prof. Sven Diederichs	Bioinformatics of ncRNAs Prof. John S. Mattick Prof. Ulf Andersson Orom Prof. Manel Esteller	ncRNA Technologies Prof. Maite Huarte Martinez
	Lunch and Poster Session	Lunch and Poster Session	Concluding Remarks
Afternoon	Translational Applications of ncRNAs as Biomarkers Prof. Carlo Croce Prof. Menashe Bar-Eli	ncRNA Therapeutics Prof. Frank J. Slack Prof. George A. Calin
	Coffee Break	Coffee Break
	Translational Applications of ncRNAs as Biomarkers Prof. Helge Grosshans Prof. Fabbri Muller Prof. Manuela Ferracin	ncRNA Therapeutics Prof. Massimo Negrini Prof. Kalpana Ghoshal Conference Dinner

Session Start

Wednesday 21 June 2017: 08:30 - 13:20 / 14:20 - 18:10
Thursday 22 June 2017: 09:00 - 13:20 / 14:20 - 18:10
Friday 23 June 2017: 09:00 - 13:20

Detailed Program

Day 1: Wednesday 21 June 2017

07:30–08:30 Check-in
08:30–08:45 Welcome – Conradin Cramer
08:45–09:00 Introduction – George A. Calin

09:00–13:20 Session 1: The Biology of ncRNAs – Sponsored by Arraystar Session Chairs: Amy Pasquinelli and Reuven Agami

09:00–09:30 Reuven Agami – Functional Genetic Screens of Regulatory DNA Elements
09:30–10:00 Amy Pasquinelli – Elucidating the Dark Side of the MicroRNA
10:00–10:20 Joost Kluiver – ZDHHC11 and ZDHHC11B are Novel Critical Components of the Oncogenic miR-150-MYBnetwork in Burkitt Lymphoma
10:20–10:40 Eleonora Candi – Ultra-Conserved Non-Coding Transcript T-UC291 Controls Somatic Tissue Differentiation by Interfering with ACTL6A
10:40–11:00 Carmen Jeronimo – A Multiplatform Approach Identifies miR-152 as a Novel Epigenetically Downregulated microRNA in Prostate Cancer

11:00–11:40 Coffee Break

11:40–12:10 Qihong Huang – Lost in Translation: Long Non-coding RNAs in Metastasis
12:10–12:40 Sven Diederichs – MALAT1 and Beyond - Long Non-coding RNAs in Lung Cancer
12:40–13:00 Daniela Zeitler – Hyper-phosphorylation of Argonaute Proteins Affects mRNA Binding and is Essential for microRNA-guided Gene Silencing
13:00–13:20 Jelena Kresoja-Rakic – lncRNA RP11-334E6.12 expression is highly correlated with increased THY-1 expression in chemoresistant primary mesothelioma cells

13:20–14:30 Lunch and Poster Session

14:30–18:20 Session 2: Translational Applications of ncRNAs as Biomarkers
Session Chairs: Carlo Croce and Menashe Bar-Eli

14:30–15:00 Carlo Croce – MicroRNA Dysregulation to Identify Therapeutic Target Combinations for Chronic Lymphocytic Leukemia
15:00–15:30 Menashe Bar-Eli – RNA Editing and Melanoma Metastasis
15:30–15:50 Stefan Eichmüller – miRNAs Modulating Melanoma Cell Invasion

15:50–16:30 Coffee Break

16:30–17:00 Helge Grosshans – Noncoding RNA Function and Regulation in Animal Development
17:00–17:30 Fabbri Muller – Role of Exosomal miRNAs in the Biology of the Tumor Microenvironment
17:30–18:00 Manuela Ferracin – Epigenetic Biomarkers of Prognosis in Stage IIA Colon Cancer
18:00–18:20 Dror Avni – Alterations of MicroRNAs Throughout the Malignant Evolution of Cutaneous Squamous Cell Carcinoma: The Role of miR-497 in Epithelial to Mesenchymal Transition of Keratinocytes

Day 2: Thursday 22 June 2017

09:00–13:10 Session 3: Bioinformatics and ncRNAs World
Session Chairs: Isidore Rigoutsos and John S. Mattick

09:00–09:30 Isidore Rigoutsos – Transcriptomic Heterogeneity: Known and Novel Short Non-coding Regulatory RNAs that Depend on Sex, Population Origin, Tissue, and Disease
09:30–10:00 Mihaela Zavolan – The 3' UTR Landscape of Human Cancers
10:00–10:20 Giovanna Brancati – Fatal Imperfections: Determinants of miRNA Target Specificity
10:20–10:40 Francisco J. Enguita – miRNAtools: Advanced Training Using the miRNA Web of Knowledge
10:40–11:00 Rory Johnson – Cancer Driver Long Noncoding RNA Discovery in the Pan-Cancer Analysis of Whole Genomes (PCAWG) Collaboration

11:00–11:40 Coffee Break

11:40–12:10 John S. Mattick – Exons are the modular unit of structure-function in regulatory RNAs
12:10–12:40 Ulf Andersson Orom – Chromatin-Release Is Important for Long NcRNA Function
12:40–13:10 Manel Esteller – Epigenetics and Epitranscriptomics of Non-Coding RNAs in Human Cancer

13:10–14:10 Lunch and Poster Session

14:10–17:50 Session 4: ncRNA Therapeutics
Session Chairs: Frank J. Slack and Massimo Negrini

14:10–14:40 Frank J. Slack – MicroRNA-Based Therapeutics in Cancer
14:40–15:10 George A. Calin – About Chomsky, Non-Coding RNA Structure and Cancer Patient's Treatment
15:10–15:30 Aniello Russo – Role of miR-125a in Hepatic Carcinogenesis

15:30–16:10 Coffee Break

16:10–16:40 Massimo Negrini – Multiple Approaches for miRNA-based Therapies of Cancer
16:40–17:10 Kalpana Ghoshal – Transcriptome-Wide Mapping of the miR-122 Targetome Revealed its Mechanistic Role in the Maintenance of Liver Homeostasis and Suppressing Hepatocarcnogenesis
17:10–17:30 Silvia Catuogno – Development of RNA Aptamers for Targeting B-cell-derived Malignancies
17:30–17:50 Alva Rani James – A Specific long non-coding RNA Expression Signature Defines the Philadelphia-like B-cell Acute Lymphoblastic Leukemia Subtype

19:00 Conference Dinner

Day 3: Friday 23 June 2017

09:00–13:20 Session 5: ncRNA Technologies
Session Chairs: Thomas Schmittgen and Manel Esteller

09:00–09:30 Thomas Schmittgen – microRNAs Shape Plasticity of Pancreatic Acini
09:30–10:00 Jo Vandesompele – Tools for lncRNA Research in Cancer
10:00–10:20 Britta Skawran – The microRNA-449 Family Inhibits TGF-β-mediated Liver Cancer Cell Migration by Targeting SOX4
10:20–10:40 Jörg Krummheuer – An Improved Algorithm for Antisense LNA™ GapmeR Design
10:40–11:00 Mattia Boeri – High Risk Plasma microRNA Signature is Associated with an Immune-related Gene Expression Profile of Lung Tumour Tissues

11:00–11:40 Coffee Break

11:40–12:00 Martin Pichler – MicroRNA-196 Influence Metastases Formation in Colorectal Cancer through Regulation of HOXB and GALNT Gene Expression
12:00–12:30 Maite Huarte Martinez – Functional long Noncoding RNAs in Cancer Pathways
12:30–12.50 Enrique Fuentes-Mattei – Plasma Viral miRNAs as Targeted-biomarkers of Occult Viral Infections Prevalence and Sepsis Aggressiveness
12:50–13:10 Paola Parrella – Stepwise Analysis of MIR9 Loci Identifies miR-9-5p to be Involved in Oestrogen Regulated Pathways in Breast Cancer Patients

13:10 Concluding Remarks

Conference Speakers

Session 1: The Biology of ncRNAs - Sponsored by Arraystar

Prof. Reuven Agami - Functional Genetic Screens of Regulatory DNA Elements
Netherlands Cancer Institute - NKI Amsterdam, The Netherlands

Prof. Amy Pasquinelli - Elucidating the Dark Side of the MicroRNA
Division of Biological Sciences, University of California, USA

Prof. Qihong Huang - Lost in Translation: Long Non-Coding RNAs in Metastasis
Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, USA

Prof. Sven Diederichs - MALAT1 and Beyond - Long Non-Coding RNAs in Lung Cancer
Division Head RNA Biology & Cancer, DKFZ - Deutsches Krebsforschungszentrum, Germany

Session 2: Translational Applications of ncRNAs as Biomarkers

Prof. Carlo Croce - MicroRNA Dysregulation to Identify Therapeutic Target Combinations for Chronic Lymphocytic Leukemia
Department of Cancer Biology and Genetics, The Ohio State University, USA

Prof. Menashe Bar-Eli - RNA Editing and Melanoma Metastasis
Department of Cancer Biology, The University of Texas, MD Anderson Cancer Center, USA

Prof. Helge Grosshans - Non-Coding RNA Function and Regulation in Animal Development
Friedrich Miescher Institute for Biomedical Research (FMI) Basel, Switzerland

Prof. Fabbri Muller - Role of Exosomal miRNAs in the Biology of the Tumor Microenvironment
Pediatrics and Molecular Microbiology and Immunology, Children's Hospital Los Angeles, University of Southern California, USA

Prof. Manuela Ferracin - Epigenetic Biomarkers of Prognosis in Stage IIA Colon Cancer
Department of Specialised, Experimental, and Diagnostic Medicine, University of Bologna, Italy

Session 3: Bioinformatics of ncRNAs

Prof. Isidore Rigoutsos - Transcriptomic Heterogeneity: Known and Novel Short Non-Coding Regulatory RNAs that Depend on Sex, Population Origin, Tissue, and Disease
Director Computational Medicine Center, Thomas Jefferson University

Prof. Mihaela Zavolan - The 3' UTR Landscape of Human Cancers
Professor in Computational Biology/Genomics, Biozentrum, University of Basel, Switzerland

Prof. John S. Mattick - Exons are the Modular Unit of Structure-Function in Regulatory RNAs
Institute Director and Head, RNA Biology and Plasticity Laboratory Senior Principal Research Fellow, Garvan Institute of Medical Research, University of New South Wales, Sydney, Australia

Prof. Ulf Andersson Orom - Chromatin-Release Is Important for Long ncRNA Function
Long non-coding RNA Research Group, Max Planck Institute for Molecular Genetics, Germany

Prof. Manel Esteller - Epigenetics and Epitranscriptomics of Non-Coding RNAs in Human Cancer
Leader of the Cancer Epigenetics Group, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

Session 4: ncRNA Therapeutics

Prof. Frank J. Slack - MicroRNA-Based, Therapeutics in Cancer
Professor, Pathology, Harvard Medical School, Professor, Pathology, Beth Israel Deaconess Medical Center, Boston, USA

Prof. George A. Calin - About Chomsky, Non-Coding RNA Structure and Cancer Patient's Treatment
The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Prof. Massimo Negrini - Multiple Approaches for miRNA-based Therapies of Cancer
Department of Morphology Surgery and Experimental Medicine, University of Ferrara, Italy

Prof. Kalpana Ghoshal - Transcriptome-Wide Mapping of the miR-122 Targetome Revealed Its Mechanistic Role in the Maintenance of Liver Homeostasis and Suppressing Hepatocarcnogenesis
Department of Pathology, The Ohio State University, USA

Session 5: ncRNA Technologies

Prof. Thomas Schmittgen - MicroRNAs Shape Plasticity of Pancreatic Acini
College of Pharmacy, University of Florida, Gainesville, USA

Prof. Jo Vandesompele - Tools for lncRNA Research in Cancer
Chair of the Cancer Research Institute, Ghent University, Belgium

Prof. Maite Huarte Martinez - Functional long Non-Coding RNAs in Cancer Pathways
Center for Applied Medical Research (CIMA), University of Navarra, Spain